Responses
Immunotherapy biomarkers
Original research
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
